Yuhan Corp

Chart & Performance

D1W1MN

P/E

100.93

P/S

3.45

EPS

961.08

Div Yield, %

—

Shrs. gr., 5y

0.74%

Rev. gr., 5y

6.91%

Revenues

2.07t

+11.23%

Net income

70.69b

-24.41%

CFO

54.60b

-62.12%

Dividend

Dec 27, 2023460 KRW/sh

Earnings

Jul 28, 2025

Profile

Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

URL

https://www.yuhan.co.kr/

IPO date

Nov 01, 1962

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	2,067,791,452 11.23%	1,858,983,760 4.68%	1,775,846,943 5.22%
Cost of revenue	1,810,827,065	1,604,933,638	1,565,143,942
Unusual Expense (Income)
NOPBT	256,964,387	254,050,122	210,703,001
NOPBT Margin	12.43%	13.67%	11.86%
Operating Taxes	6,268,415	4,708,853	4,333,847
Tax Rate	2.44%	1.85%	2.06%
NOPAT	250,695,972	249,341,269	206,369,154
Net income	70,687,449 -24.41%	93,509,564 -1.72%	95,144,301 -7.25%
Dividends	(32,145,147)	(27,268,933)	(26,079,622)
Dividend yield	0.36%	0.50%	0.64%
Proceeds from repurchase of equity	(2,512,349)	(7,457,004)	(16,521,185)
BB yield	0.03%	0.14%	0.40%
Debt
Debt current	180,671,778	299,864	91,966,049
Long-term debt	124,843,264	634,634	7,661,539
Deferred revenue	651,543		400,000
Other long-term liabilities	49,229,564	128,978,124	(62,467,892)
Net debt	(522,402,719)	(939,539,381)	(815,343,670)
Cash flow
Cash from operating activities	54,601,585	144,128,102	99,528,971
CAPEX	(117,078,953)	(161,479,680)	(94,378,310)
Cash from investing activities	(117,369,101)	(187,075,209)	15,621,385
Cash from financing activities	65,836,368	51,092,658	(65,541,959)
FCF	(140,575,154)	299,506,301	131,024,232
Balance
Cash	330,702,645	322,003,511	347,718,179
Long term investments	497,215,115	618,470,368	567,253,079
Excess cash	724,528,188	847,524,691	826,178,911
Stockholders' equity	2,141,542,727	2,154,226,373	3,782,398,430
Invested Capital	1,728,929,032	1,606,976,466	1,188,312,448
ROIC	15.03%	17.84%	17.71%
ROCE	10.26%	12.43%	10.01%
EV
Common stock shares outstanding	74,960	78,714	75,185
Price	119,500.00 73.69%	68,800.00 26.29%	54,476.19 -12.28%
Market cap	8,957,741,510 65.41%	5,415,507,582 32.22%	4,095,773,878 -12.75%
EV	8,486,646,638	4,475,968,201	3,303,586,931
EBITDA	320,005,617	298,733,188	253,721,514
EV/EBITDA	26.52	14.98	13.02
Interest	14,729,724	2,455,080	3,468,047
Interest/NOPBT	5.73%	0.97%	1.65%